OncoMatch/Clinical Trials/NCT05704647
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Is NCT05704647 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BMS-986213 (Relatlimab-Nivolumab FDC) and Nivolumab for melanoma (skin).
Treatment: BMS-986213 (Relatlimab-Nivolumab FDC) · Nivolumab · Relatlimab — To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Melanoma
Biomarker criteria
Required: PD-L1 (CD274) expression (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: checkpoint inhibitor in the metastatic setting
Exception: adjuvant/neoadjuvant ipilimumab and/or anti-PD1 allowed if ≥6 months washout
Prior checkpoint inhibitor therapy in the metastatic setting. Patients who received ipilimumab and/or anti-PD1 as adjuvant or neoadjuvant therapy must have a 6-month washout before receiving any dosing on this study.
Cannot have received: whole brain radiation
Prior whole brain radiation is not allowed
Lab requirements
Blood counts
Adequate organ function as described below.
Kidney function
Adequate organ function as described below.
Liver function
Adequate organ function as described below.
Adequate organ function as described below.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05704647 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior checkpoint inhibitor in the metastatic setting, whole brain radiation disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages